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ABSTRACT
Background: Nasopharyngeal carcinoma (NPC) is a malignancy with remarkable geographic and distribution worldwide, towards in Southern China 
and Southern Asia. In addition to Epstein-barr virus infection, environmental carcinogens, the development of NPC involves the cumulative genetic as 
well as epigenetic alteration. More recently, it has been reported that DNA hypermethylation, an epigenetic mechanism, that occurred by the addition 
of a methyl group at 5’ position of the pyrimidine ring of Cytosine residues at CpG islands, has been considered as the cause of nasopharyngeal 
tumorigenesis. In recent years, many reports have focused on the identification, evaluation of aberrant methylation of target tumor suppressor genes’ 
promoters, such as RASSF1A, Blu, DLEC, RARβ, p16, p15, p14, MGMT, etc. in the NPC development. 
Objective and Method: In this review, we summarized and focused on the description and exemplification of the DNA hypermethylation changes, 
particularly, highlight the DNA hypermethylation as a potential biomarker applied in monitoring, screening, early diagnosis for cancer of nasopharynx.
Conclusion: Measuring and detecting the hypermethylation status of TSGs could be served as potential, and promising biomarkers for monitoring, 
early screening and diagnosis of human cancers.
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INTRODUCTION
Nasopharyngeal carcinoma (NPC), arises from the epithelium of the 
nasopharynx, is the most common malignant tumor of head and 
neck cancer with a remarkable geographic and racial distribution 
worldwide [1-3]. There is a striking distribution of NPC, which 
encounters in Southern China, Singapore, Vietnam, Malaysia, and 
the Philippines. On the contrary, it is also fairly common in Europe, 
USA, Northwest Canada, and Greenland [1,4,5]. According to the 
etiological factors of NPC, many previous studies suggested that there 
are several cofactors that are associated with NPC development. The 
major etiological factors proposed for NPC pathogenesis include the 
dietary factors, the infection with an oncovirus, named Epstein–Barr 
virus (EBV), a gamma herpes virus discovered in 1964 by Epstein 
et al. [5,6], and genetic-epigenetic factors, in a multistep carcinogenic 
process [3,7,8]. The remarkable racial and geographic distribution of 
NPC suggests the strong association of NPC with genetic susceptibility 
and environmental factors [7]. Based on the previous studies, a 
collaborative model for NPC tumorigenesis driven by specific genetic 
alteration, EBV infection, and environmental factors is proposed (Fig. 1). 
The viral risk factors and environmental factors for NPC discussed 
separately in many previous studies; therefore, this article will focus 
primarily on the epigenetic alterations, including the promoter hyper 
methylation, in NPC tumorigenesis.
DNA HYPERMETHYLATION AND CANCER
In contrast to the genetic alterations, epigenetic regulations, which were 
first coined by Waddington in 1942, means as “outside conventional 
genetics,” refer to the heritable, reversible changes in gene expression 
that does not change the sequence of genome [9]. Recent advances in the 
field of epigenetics have shown that epigenetic modification is the natural 
processes and essential for mammalian development and cell proliferations 
that affect gene products at multiple levels, including transcriptional level, 
post-transcriptional regulation, leading to the great diversity to the gene 
regulation network [9,10]. In the case of improperly occurred, they could 
be the major cause of health and normal development. Three main types 
of epigenetic modification systems, including DNA methylation, histone 
covalent modification, and non-coding RNA modification, leading to 
associated-gene disrupted, have been identified [11-13]. The pattern of 
hypermethylation, one of the two aberrant methylations, at the specific 
sites, namely, the CpG islands (CGIs) at the tumor suppressor genes 
(TSGs)’ promoter region, leads to the increasing of level of methyl group 
modification, is an important mechanism of a number of TSG inactivation 
[14-17]. This methylation process is catalyzed by DNA (cytosine-5)-
methyltransferases (DNMTs). In mammalian, DNMTs are a highly 
conversed family protein encompassing DNMT1, DNMT2, DNMT3A, 
DNMT3B, and DNMT3L, which could be distinguished by their function 
[18-20]. DNMT1, which functions as the major maintenance of the 
existence of methylation patterns following DNA replication on the newly 
synthesized, was the first methyltransferase to be discovered. DNMT3A 
and DNMT3B perform de novo methylation by adding the methyl groups 
to unmethylated CpG, which is responsible for the establishment of new 
methylation pattern in genomic [20-22]. DNMT3L has no catalytic activity, 
and it has been shown to act as a general stimulatory factor for de novo 
methylation and facilitate methylation of DNMT3A and DNMT3B [23-25]. 
The hypermethylated CGIs at promoter region prevent the binding of RNA 
polymerase and transcription factors, such as AP-2, c-Myc/Myn, E2F, and 
NF-κB, as the results inhibit the TSGs transcription [10,20] (Fig. 2). The 
hallmark of cancer involves the loss of the function of TSGs through the 
silencing genetic information. The silencing of TSGs by the high levels of 
5-methylcytosine in their CGI promoter regions, considered as the “first 
and second hit,” is equivalent to mutation and translocations, in Knudson’s 
two-hit model of tumorigenesis [26,27]. Thus, the presence of m5CpG 
dinucleotide in TSGs’ promoters is recognized as an important event in 
many human cancers.
DNA HYPERMETHYLATION IN NPC: BIOMARKERS FOR NPC 
DIAGNOSIS AND PROGNOSIS
Previous studies suggested that NPC is associated with the accumulation 
of many epigenetic alterations on the particular chromosomal regions 
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and genes, including the alterations involve both TSGs and proto-
oncogenes on multiple cellular pathways, which further contribute to 
the malignant cancer hallmarks [2,8,10]. Interestingly, recent studies 
confirm that epigenetic alterations, including the hypermethylation, 
are also one of the crucial factors that are highly associated with 
NPC development. According to the research of Dai et al., in their 
comparative methylome study, as the compared to nine other human 
cancer types, including liver, head and neck, colon, lung, thyroid, kidney, 
breast, pancreatic, and prostate cancer, they found that NPC had the 
highest hypermethylation frequency [28]. Many studies demonstrated 
that the inactivation of TSGs located on chromosome 3p, 9p, 9q, 11q, 
13q, 14q, and 16q is the common and important events in the NPC 
tumorigenesis and development, as summarized in Table 1 [8,29-32]. 
Representatively, the most frequently hypermethylation is reported in 
critical regions on chromosome 3p in NPC, as noted in Table 1.
Previous studies have shown that the inactivation of TSGs, which 
were located in chromosome 3, was significant associated with the 
development of NPC. Given the aberrant methylation frequently 
observed in NPC, we, therein, evaluated the status of methylation 
biomarkers for NPC detection, as summarized in Table 2. Based on 
Table 2, it suggested that ZMYND10, RASSF1A, DLEC1, and RARβ 
promoter hypermethylation are more frequent in NPC than in non-
cancerous samples. Given examples, the well-known suppressor gene, 
RASSF1A, located at 3p21.31, according to the systematical analysis 
of RASSF1A promoter methylation in NPC, Ye et al. suggested that, 
comprised 11 studies forming a large population, RASSF1A promoter 
methylation is significantly increased and notably common in NPC 
tissue samples compared with non-tissue samples, which indicated 
that hypermethylation of the RASSF1A promoter is closely linked to 
NPC tumorigenesis. In addition, they found that the pooled specificity 
and AUC of RASSF1A promoter hypermethylation were very good 
in tissue, brushing, and blood samples in the cases of NPC patients 
versus corresponding non-tumor samples [45]. Up to now, many 
studies relevant to the determination of combination many TSGs 
inactivated by promoter hypermethylation were carried. As the report 
of Kwong et al. [40], they have analyzed the promoter hypermethylation 
pattern of panel of eight TSGs, including RASSF1A (3p21.31), RARβ2 
(3p24.2), DAPK (9p21.33), p16 (9p21.3), p15 (9p21.3), p14 (1q42.13), 
MGMT (10p26.3) and GSTP1 (11q13.2). They reported that the 
high frequency of promoter hypermethylation of multiple cancer-
related genes as well as at least one of eight genes showed aberrant 
methylation in all samples, provides an opportunity that the promoter 
hypermethylation may be used for the clinical diagnosis of NPC. In 
addition, more recent work has used next-generation sequencing (NGS) 
techniques, which has emerged as a powerful method to characterize 
the methyl changes in high resolution as well as to profile DNA 
hypermethylation across a whole genome or large regions of a genome, 
which is expected to be affordable for most research centers in the near 
future [46,47]. The advent of NGS techniques opens the possibility 
of discovery studies that quantify DNA methylation patterns and 
differences in DNA methylation could be served as potential biomarkers 
for the clinical diagnosis and screening of NPC.
METHYLATED CIRCULATING DNA AS A NASOPHARYNGEAL 
CANCER BIOMARKER
Recent advance technologies in the detection and characterization 
circulating tumor DNA (ctDNA) may address the great promise for 
the early detection and management of human cancers. Even in 
the early stage, ctDNA is considered to be easily detected in plasma 
of cancer patients [48,49]. In comparison to application of tissue 
biopsies in cancer detection, ctDNA, which fully representing tumors 
and is released into circulation by various pathologic and mechanism, 
represents a non-invasive, high specificity, sensitivity method for 
tumor diagnosis, and monitoring [48,50]. In addition, ctDNA could 
be distinguished from circulating DNA derived from healthy cells by 
the presence of genomic aberrant modifications [51]. The feasibility 
of using ctDNA in cancer detection has been demonstrated in many 
human cancers, including NPC. Given example, according to Wong 
et al., 2004, they evaluated the proposed diagnosis value of quantitative 
measurement of plasma DNA concentration and hypermethylated DNA 
markers, including panel of genes, CDH1, DAPK1, p15, p16, RASSF1A, 
Fig. 1: Pathogenesis model for nasopharyngeal carcinoma
Fig. 2: The typical CpG island of a tumor suppressor gene is 
represented in a normal and a tumor cell [20]. White dots: 
Unmethylated CpG; black dots: Methylated CpG. AdoMet: 
S-adenosylmethionine. AdoHcy: S-adenosylhomocysteine. DNMTs: 
DNA (cytosine-5)-methyltransferases
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and MLH1, in undifferentiated NPC patients. As the results, they found 
that methylated DNA was detectable in plasma of NPC patients, and the 
frequencies of CDH1, DAPK1, p15, p16, and RASSF1A were 46%, 42%, 
20%, 20%, and 5%, respectively. In contrast, the hypermethylation of 
MLH1 was not detected in plasma of all of the NPC patients and normal 
individuals. Moreover, they found that aberrantly hypermethylated 
promoter DNA at least one of five genes detectable in 29 of 41 (counting 
for 71%) plasma of NPC patients. Thus, their results demonstrated that 
hypermethylated genes could be detected in the plasma of NPC patients, 
suggesting that hypermethylated gene might be used as a serological 
tumor marker in screening of primary NPC [52]. In summary, based 
on the circulating methylated gene promoter DNA is a possibly useful 
biomarker for diagnoses, prognoses, and guidance for treatments.
CONCLUSION
NPC is characterized with multiple hallmarks including the EBV 
infection, dietary factors, and genetic-epigenetic factors. The 
hypermethylation of TSG promoter, epigenetic alteration, has been 
shown to be a specific event that interplays during NPC initiation and 
progression. Measuring and detecting the hypermethylation status of 
TSGs derived from tissue biopsies as well as the ctDNA dynamics in body 
fluids such as blood, or serum is a novel area and developing research, 
additionally, it is considerably served as potential, great versatility and 
promising biomarkers for monitoring, early screening, and diagnosis of 
human cancers, including NPC.
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